查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1820258

流感疫苗市场规模、份额和趋势（按疫苗类型、技术、年龄层、给药途径、地区划分）及预测（2025-2033 年）

Influenza Vaccine Market Size, Share, and Trends by Vaccine Type, Technology, Age Group, Route of Administration, Region, and Forecast 2025-2033
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球流感疫苗市场规模为72亿美元。展望未来， IMARC Group估计，到2033年，市场规模将达到128亿美元，2025年至2033年期间的复合年增长率为6.7%。北美目前占据市场主导地位，2024年的市占率将超过53.4%。支持流感疫苗市场成长的一些关键因素包括政府机构推出许多积极措施来支持疫苗接种计画、流感病例和季节性疫情的增加，以及更有效、保护更广泛的流感疫苗。

全球流感疫苗市场正在经历成长，这得益于多种因素，例如人们对季节性流感的认识不断提高以及医疗保健支出的增加。老年人口的增加更容易因流感感染而引起併发症，这也是另一个驱动因素。世界各国政府都在投入资源疫苗接种计画。这反过来又对市场的成长产生了正面的影响。 COVID-19 大流行强化了预防医学的合理性，从而增加了流感疫苗的接种率，因为许多人开始意识到预防比治疗更重要。随着基于 mRNA 的疫苗等新疫苗开发方法的出现，疫苗的安全性和有效性得到了改善。此外，由于流感病毒株数量的增加以及个人每年接种疫苗的要求，疫苗需求持续存在。医疗设施的兴起，特别是在发展中国家，可能会进一步增加疫苗的使用和接受度。

美国已成为流感疫苗的关键区域市场。截至 2024 年 11 月，美国已为 2024-25 年度分发了 1.3419 亿剂流感疫苗。美国的疫苗供应很大程度上依赖私营製造商，预计本季流感疫苗供应总量为 1.48 亿剂。供应量的增加反映了美国流感疫苗市场需求的成长，这种需求是由预防季节性疫情的需求所推动的，尤其是在老年人和慢性病患者等高风险族群。在四价疫苗和 mRNA 疫苗等疫苗技术创新的推动下，以及在政府疫苗接种计画的支持下，美国流感疫苗市场持续扩大。随着疫苗可及性和有效性的不断提高，製造商正在响应更高的需求预测，为市场持续成长做好准备。

流感疫苗市场趋势：

季节性流感疫情和疫情日益增多

季节性流感病例的增加导致住院率上升。例如，在 2022-2023 年流感季节，美国有 3,100 万例流感病例。此外，在 2021-2022 年流感季节，流感导致 4,977 人死亡。除此之外，美国很大一部分人口未能接种疫苗。此外，在 2021-2022 年，只有 37% 的 18 至 49 岁人群接种了流感疫苗，与儿童和老年人相比要低得多。因此，医疗机构越来越重视流感疫苗接种的重要性，这促进了市场的成长。例如，2023 年 2 月，世界卫生组织 (WHO) 宣布了 2023-2024 年流感季节流感疫苗病毒组成的建议。这项消息是在为期四天的流感病毒疫苗成分会议结束时的资讯发布会上宣布的。

流感疫苗接种意识不断提高

季节性流感的日益普及主要促进了市场的成长。例如，2022 年 2 月发布的全球流感资料提到，全球约有 10 亿人感染了季节性流感。与此相符的是，该报告还指出，在这 10 亿人中，每年约有 300 万至 500 万人患有严重流感。此外，根据世界卫生组织 2022 年 12 月发布的资料，欧洲地区有 5%-15% 的人口受到流感的影响。同样，2021 年 7 月发表的 Plos One Journal 文章提到，每年约有 5%-10% 和 20%-30% 的新流感感染病例发生在儿童和成人身上。流感病毒病例的增加提高了人们对流感疫苗接种的认识，这为整体市场成长提供了积极的前景。除此之外，医疗保健机构正在进行宣传活动，宣传免疫接种的益处，进而推动流感疫苗的需求。例如，赛诺菲在2022年6月进行的一项医疗保健调查显示，药剂师和医生建议美国疾病管制与预防中心（CDC）为65岁及以上人口提供类似Fluzone高剂量四价疫苗的流感治疗。各年龄层日益增长的接种意愿将在预测期内继续推动流感疫苗市场份额的成长。

政府机构的支持日益增强

世界各国政府机构正与领先公司合作，以促进流感疫苗的研发工作。根据流感疫苗市场的统计数据，2021 年 9 月，美国疾病管制与预防中心 (CDC) 加入了由生物医学高级研究与发展局 (BARDA) 牵头的广泛跨机构合作伙伴关係，该合作伙伴关係为新型流感疫苗的高级研发提供资金。此外，政府机构正在简化和升级许可证审批程序，这有助于流感疫苗市场的需求成长。例如，2022 年 7 月，美国 FDA 批准了葛兰素史克公司对四价流感疫苗 Fluarix 的授权申请。为此，政府正投入资金用于流感疫苗的临床试验和研发工作。例如，2022 年 3 月，澳洲政府实体为高风险族群接种季节性流感疫苗花费了超过 1 亿美元。除此之外，大型医疗保健公司正在大力投资疫苗方面的创新先进疗法的推出，从而也对流感疫苗市场前景产生正面影响。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球流感疫苗市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依疫苗类型

  • 四价
  • 三价

第七章：市场区隔：依技术

  • 鸡蛋为主
  • 基于细胞

第八章：市场区隔：依年龄段

  • 儿科
  • 成人

第九章：市场细分：依行政途径

  • 注射
  • 鼻喷剂

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112025A4206

The global influenza vaccine market size was valued at USD 7.2 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 12.8 Billion by 2033, exhibiting a CAGR of 6.7% from 2025-2033. North America currently dominates the market, holding a market share of over 53.4% in 2024. Some of the key factors supporting the influenza vaccine market growth include the launch of many positive initiatives by government bodies to support vaccination programs, increasing cases of influenza and seasonal outbreaks, and more effective and broadly protective influenza vaccines.

The global influenza vaccine market is witnessing growth on account of several factors, factors such as rising awareness regarding the seasonal flu and increasing healthcare spending. The increasing elderly population who are more prone to complications arising from flu infections is also another driving factor. Governments worldwide are channeling resources into vaccination programs. This in turn contributes positively toward the growth of the market. The COVID-19 pandemic reinforced the rationale for preventive medicine, thus increasing the uptake of flu vaccines, as many people began to understand the importance of prevention over treatment. With new ways of developing vaccines such as mRNA-based vaccines, safety, and efficiency of vaccines have improved. Moreover, due to the rising number of influenza strains, and the requirement that individuals be vaccinated every year, there is perpetual demand. The rise of health care facilities particularly in developing countries is likely to increase further the usage and acceptance of vaccines.

The United States has emerged as a key regional market for influenza vaccines. As of November 2024, the US has distributed 134.19 million doses of the flu vaccine for the 2024-25 season. Vaccine supply in the U.S. largely depends on private manufacturers, with projections for a total of 148 million doses of influenza vaccine for the current season. This increasing supply reflects the growing demand within the influenza vaccine market in the U.S. market, driven by the need to prevent seasonal outbreaks, particularly among high-risk populations such as the elderly and those with chronic conditions. The influenza vaccine market in the U.S. continues to expand, bolstered by innovations in vaccine technology, such as quadrivalent and mRNA vaccines, and supported by government vaccination programs. With ongoing improvements in vaccine accessibility and efficacy, manufacturers are responding to higher demand projections, positioning the market for continued growth.

Influenza Vaccine Market Trends:

Increasing Seasonal Influenza Outbreaks and Pandemics

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. Additionally, in 2021-2022, only 37% of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

The Rising Awareness Towards Influenza Vaccination

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

The Growing Support from Government Bodies

Government agencies around the world are partnering with leading companies to facilitate R&D work in the development of influenza vaccines. According to the statistics of the influenza vaccine market, in September 2021, the Centers for Disease Control and Prevention (CDC) joined a broad interagency partnership led by the Biomedical Advanced Research and Development Authority (BARDA) that funded the advanced development of new influenza vaccines. In addition, government bodies are streamlining and upgrading the procedure of license approvals, which is contributing to the growth in demand in the flu vaccine market. For instance, in July 2022, the U.S. FDA sanctioned the appeal from GlaxoSmithKline for the license Fluarix, which is a quadrivalent flu vaccine. To this effect, the government is spending on clinical trials and R&D work on the development of flu vaccines. For example, during March 2022, Australia's governmental entities spent more than USD 100 Million for seasonal influenza vaccination against individuals under high risk. In addition to this, giant health-care corporations are significantly investing in the release of innovative advanced therapies in terms of vaccines, thus also influencing positively in the case of the influenza vaccine market outlook.

Influenza Vaccine Industry Segmentation:

Analysis by Vaccine Type:

  • Quadrivalent
  • Trivalent

Quadrivalent stands as the largest vaccine type in 2024, holding over 69% of the market. Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

Analysis by Technology:

  • Egg-based
  • Cell-based

Egg-based leads the market with around 69% of market share in 2024. Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1) pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Analysis by Age Group:

  • Pediatric
  • Adult

Pediatric leads the market with over 72% of market share in 2024. Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

Analysis by Route of Administration:

  • Injection
  • Nasal Spray

The injection segment remains widely used, particularly intramuscular injections. This segment is expected to grow rapidly due to advancements in injection technologies, such as the development of microneedle patches that aim to simplify administration and improve patient compliance.

On the other hand, nasal spray influenza vaccines provide a needle-free alternative to traditional injections, delivering the vaccine via the nasal mucosa to stimulate a mucosal immune response. Though less common than injectable vaccines, nasal spray options are increasingly favored by individuals, especially children, who may have a fear of needles. The segment is seeing growth due to ongoing research aimed at improving formulations, expanding eligibility to a broader age range, and refining the delivery technology.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 53%. In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins

Key Regional Takeaways:

United States Influenza Vaccine Market Analysis

In 2024, the Unites States accounts for over 70% of the influenza vaccine market in North America. Strong government initiatives, a strong healthcare system, and an aging population are the main factors propelling the industry. Increasing vaccine uptake is largely dependent on the Centers for Disease Control and Prevention's (CDC) annual vaccination efforts. Between 9 and 45 million influenza cases are estimated to occur in the United States each year, according to the CDC, with related hospitalizations and deaths underscoring the importance of prevention. For vulnerable populations, including the elderly, small children, pregnant women, and people with long-term medical issues, influenza vaccination is strongly advised. Interestingly, more than 16% of Americans are 65 years of age or older, a demographic that has far greater influenza complications and is therefore a prime target for vaccination campaigns.

Additionally, technological developments have fueled market expansion. The effectiveness and coverage of vaccines have increased since the advent of quadrivalent vaccines, which offer protection against four influenza strains. The drawbacks of conventional egg-based vaccinations have been overcome by cell-based and recombinant technologies, which shorten production times and increase scalability during epidemics. Innovations like mRNA-based flu vaccines, which promise increased efficacy and quick adaptation to new strains, are the result of pharmaceutical companies like Sanofi, GlaxoSmithKline, and Moderna investing more in research and development. The industry is further supported by public-private collaborations, such as those made possible by the Biomedical Advanced Research and Development Authority (BARDA). Furthermore, a wider population may now get vaccines because to employer-sponsored immunization programs, pharmacy flu clinics, and growing awareness campaigns. The market for influenza vaccines in the US is expected to expand steadily due to this combination of reasons.

Europe Influenza Vaccine Market Analysis

Adoption of influenza vaccines in Europe is being driven by aging populations, universal healthcare systems, and strict government regulations. Free flu vaccination programs have been put in place in nations including the UK, Germany, and France for vulnerable populations, such as the elderly and children. The demand is being driven by the European Centre for Disease Prevention and Control (ECDC), which places emphasis on reaching a 75% immunization target in high-risk populations. The necessity of vaccination has been further highlighted by the rise in comorbidities such as diabetes and cardiovascular disorders, which exacerbate flu-related consequences. With large expenditures in vaccine production facilities, Europe's emphasis on pandemic preparedness also boosts the industry. Large-scale awareness campaigns and school-based immunization programs that target younger populations boost the industry. The growth of mRNA-based flu vaccines in Europe is another emerging driver, offering improved efficacy and rapid production cycles.

Asia Pacific Influenza Vaccine Market Analysis

Large-scale government vaccination initiatives, growing public awareness, and rising healthcare costs all contribute to the market's growth. Leading nations include China, South Korea, and Japan, with Japan attaining yearly immunization rates of more than 50% among its senior citizens. Due to the great potential for influenza transmission, widespread vaccination campaigns are required in densely populated nations like China and India. To increase vaccine access, especially in remote areas, governments are spending money on distribution networks and cold chain infrastructure. Rapid urbanization in emerging nations increases vulnerability to influenza outbreaks and raises demand for vaccines. Furthermore, partnerships between regional producers and international pharmaceutical firms are stimulating innovation, and current clinical studies for next-generation vaccines-like those based on mRNA and intranasal formulations-are expected to propel further expansion.

Latin America Influenza Vaccine Market Analysis

The growing prevalence of seasonal flu and the government's increased emphasis on public health are driving the influenza vaccination industry in Latin America. Brazil and Mexico are important markets because of their sizable populations and pro-immunization laws. Through national immunization programs, governments frequently give away free vaccines to vulnerable populations, like children and the elderly. According to a report by International Federation on Ageing, Brazil has one of the highest rates of influenza vaccination worldwide among older persons (98.2%) and people with long-term illnesses (86.3%) in 2019. The robust government-led influenza vaccination effort, which depends on both in-person and remote mobilization, is primarily responsible for the target populations' compliance.

Middle East and Africa Influenza Vaccine Market Analysis

Growing government initiatives, foreign aid, and growing awareness of preventative healthcare are the main factors propelling the market. To avoid widespread epidemics, nations like Saudi Arabia and the United Arab Emirates have made flu vaccination a priority, especially for pilgrims traveling for events like the Hajj. Accessibility is increased by the WHO's Global Influenza Strategy, which funds immunization campaigns in low- and middle-income African nations. Uptake of the influenza vaccine is increasing in South Africa, where yearly immunization campaigns target vulnerable populations and healthcare staff. Partnerships with international health groups to improve vaccine distribution and awareness are helping to mitigate issues like the lack of adequate healthcare facilities in some areas.

Competitive Landscape:

Key players in the influenza vaccine market are significantly driving the market growth through strategic initiatives. These companies are focusing on enhancing vaccine efficacy with advanced technologies like quadrivalent and mRNA-based vaccines, expanding accessibility through partnerships with governments and healthcare providers, and engaging in extensive research and development. Manufacturers are also responding to rising demand by improving vaccine production capacity, with companies like Moderna and AstraZeneca exploring new formulations and delivery methods, such as microneedle patches, to increase patient compliance. Furthermore, these key players are involved in global vaccine distribution, ensuring greater reach and contributing to the overall market expansion.

The report provides a comprehensive analysis of the competitive landscape in the influenza vaccine market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • AstraZeneca plc
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • SINOVAC

Key Questions Answered in This Report

  • 1.What is influenza vaccine?
  • 2.How big is the influenza vaccine market?
  • 3.What is the expected growth rate of the global influenza vaccine market during 2025-2033?
  • 4.What are the key factors driving the global influenza vaccine market?
  • 5.What is the leading segment of the global influenza vaccine market based on the vaccine type?
  • 6.What is the leading segment of the global influenza vaccine market based on technology?
  • 7.What is the leading segment of the global influenza vaccine market based on age group?
  • 8.What are the key regions in the global influenza vaccine market?
  • 9.Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2024
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2024
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2024
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million USD), 2025-2033
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million USD), 2025-2033
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players